Skip to main
EVH
EVH logo

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 53%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health Inc. exhibits strong growth potential through its ability to cross-sell services and expand its risk-based products, with expectations for substantial long-term revenue growth driven by key contracts like the Aetna agreement, projected to exceed $2 billion annually. The company's substantial addressable market is emphasized by its ability to service a significant portion of the oncology sector, where it manages around 180,000 cancer cases annually amid over 2 million total cases, suggesting significant room for expansion. Additionally, a robust contract pipeline valued at $650 million and a consistent track record of exceeding revenue growth targets reinforce Evolent's position as a leader in specialty-focused value-based care, supported by favorable industry trends towards value-based payment models.

Bears say

Evolent Health Inc. is facing significant revenue challenges, with projections indicating a decline in non-enhanced revenue from approximately $285 million in 2025 to $170 million in 2026, largely due to expected drops in exchange and Medicaid membership. The company's forecast for 2026 EBITDA has been revised downward to a range of $134-$144 million, factoring in anticipated membership losses and only a modest benefit from AI-related efficiency initiatives. Additionally, Evolent's Q4 revenue outlook suggests a sequential decline of $8-$18 million, further highlighting the pressing concerns surrounding its profitability and financial stability.

Evolent Health (EVH) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 53% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 15 analysts, Evolent Health (EVH) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.